US FDA Launches Quality Maturity Pilots That Reward High-Performing OTC, Rx Manufacturers

One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”